RJA
DRNA

Raymond James & Associates’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Raymond James & Associates’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-22,207
Closed -$448K – 4351
2021
Q3 		$448K Sell
22,207
-13,628
-38% -$376K ﹤0.01% 3144
2021
Q2 		$1.34M Buy
35,835
+6,563
+22% +$201K ﹤0.01% 2390
2021
Q1 		$748K Buy
29,272
+7,148
+32% +$183K ﹤0.01% 2709
2020
Q4 		$487K Sell
22,124
-371
-2% -$8.17K ﹤0.01% 2825
2020
Q3 		$405K Buy
22,495
+17
+0.1% +$352 ﹤0.01% 2774
2020
Q2 		$571K Sell
22,478
-155
-0.7% -$3.34K ﹤0.01% 2501
2020
Q1 		$416K Sell
22,633
-1,978
-8% -$38.4K ﹤0.01% 2545
2019
Q4 		$542K Buy
24,611
+165
+0.7% +$3.32K ﹤0.01% 2671
2019
Q3 		$351K Buy
+24,446
New +$349K ﹤0.01% 2911

Other funds holding DRNA

CAM
Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Raymond James & Associates's DRNA Position: Q4 2021 in Review

Raymond James & Associates sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 22,207 shares — an estimated $448K sold.

Raymond James & Associates first reported a position in DRNA in Q3 2019 and held it in 9 quarters. The position peaked at $1.34M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

  • Raymond James & Associates reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Raymond James & Associates sold 22,207 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $448K.
  • Raymond James & Associates first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2019 and held it in 9 quarters.
  • Raymond James & Associates's Dicerna Pharmaceuticals, Inc. position peaked at $1.34M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.